Previous Page  21 / 22 Next Page
Show Menu
Previous Page 21 / 22 Next Page
Page Background

Page 52

Volume 2

Journal of Microbiology and Biotechnology Reports

Microbial Biotechnology 2018

September 17-18, 2018

Microbial Biotechnology & Vaccine Design

September 17-18, 2018 Lisbon, Portugal



World Congress on

Colon cancer stem cell-based vaccine reduces efficiently both tumor growth and cancer stem cell

subpopulation in a mouse colon carcinoma mouse model

Jun Dou, Mei Guo, Fengshu Zhao, Di Wu, Miao Li, Meng Pan, Jing Wang and Fangfang Shi

Southeast University, China

Statement of the Problem:

Colon cancer is the most common malignant gastrointestinal cancers that are still the most frequent

cause of cancer-related mortality in China. Colon Cancer Stem Cells (CCSCs) are the main reasons that result in the drug and

radiation resistance, invasive growth, metastasis and cancer relapse. Though many factors involving immuno surveillance and

immunosuppression were recently validated as important for patient prognosis, a lot of experimental immunotherapies to fight

unresectable metastatic colorectal cancer, only few cases have successfully induced antitumor immune response against malignancies.

The aim of this work was to investigate the effects on the inhibition of colon cancer growth by vaccination of CCSC vaccines.


The CD133


CSCs were isolated from human LOVO and mouse CT26 cell lines by using a magnetic-activated cell sorting

system, respectively. The xenograft or syngeneic mice were subcutaneously inoculated with the LOVO or CT26 CD133



vaccine inactivated with again and again freeze thawing three times before the mice were challenged subcutaneously with LOVO

or CT26 cells. The inhibition tumor efficacy was assessed by the tumorigenicity, immune efficient analysis by flow cytometer and

enzyme-linked immunosorbent assays, respectively.


The results showed that, compared with the non-CSC vaccine, the inhibition tumor growth efficacy of LOVO or CT26 CSC

vaccine was significantly increased in the xenograft or syngeneic mice. Vaccination of LOVO or CT26 CD133


CSC vaccine resulted

in increasing cytotoxic activity of natural killer cells, enhancing serum IFN-γ and decreasing TGF- β levels in the mice. The LOVO

and CT26 CD133


CSC vaccines significantly reduced the CSC subpopulations in the colon cancer tissues.


The data provided the first evidence that the human LOVO or mouse CT26 CD133


CSC-based vaccine may be an

attractive therapeutic approach to excitation of anti-tumor immunity for treatment of colon cancer.

Jun Dou et al., J Microbio and Biotech Rept 2018, Volume 2